Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Xenetic Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology
Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 6th Annual Israel Conference
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Xenetic Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Two Key Appointments
Xenetic Biosciences, Inc. Provides Development Update for Its Personalized CAR T Platform Technology, XCART(TM)
